SELLAS Life Sciences (SLS) Operating Leases (2019 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Operating Leases of $871000.0 for Q1 2026, up 181.88% year-over-year from $309000.0 in Q1 2025, and up 90.59% quarter-over-quarter from $457000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Operating Leases (2019 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Operating Leases for 8 consecutive years, with $871000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases rose 181.88% year-over-year to $871000.0; the TTM figure through Mar 2026 stood at $871000.0 (up 181.88% YoY), while the FY2025 annual figure was $457000.0, changed 0.0% from the prior year.
- Operating Leases rose to $871000.0 in Q1 2026 per SLS's latest filing, from $457000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $1.1 million in Q2 2022 and bottomed at $161000.0 in Q2 2024.
- Historically, Operating Leases has averaged $637437.5 across 5 years, with a median of $610000.0 in 2023.
- Annual changes were most pronounced in 2024 — Operating Leases tumbled 78.5% — and 2025, when it soared 357.76%.
- SELLAS Life Sciences' Operating Leases stood at $573000.0 in 2022, then declined by 19.72% to $460000.0 in 2023, then fell by 0.65% to $457000.0 in 2024, then changed by 0.0% to $457000.0 in 2025, then soared by 90.59% to $871000.0 in 2026.
- Business Quant data shows SLS's Operating Leases at $871000.0 in Q1 2026, $457000.0 in Q4 2025, and $737000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 737,000.00 |
| Mar 31, 2026 | 871,000.00 |
| Dec 31, 2025 | 457,000.00 |
| Jun 30, 2025 | 737,000.00 |
| Mar 31, 2025 | 309,000.00 |
| Dec 31, 2024 | 457,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 161,000.00 |
| Mar 31, 2024 | 313,000.00 |
| Dec 31, 2023 | 460,000.00 |
| Sep 30, 2023 | 644,000.00 |
| Jun 30, 2023 | 749,000.00 |
| Mar 31, 2023 | 849,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Mar 31, 2022 | 883,000.00 |
| Dec 31, 2021 | 610,000.00 |
| Sep 30, 2021 | 857,000.00 |
| Jun 30, 2021 | 903,000.00 |